Effects of sodium-glucose transporter 2 inhibitors in patients with lupus nephritis: a before-and-after retrospective cohort study
Authors:
- 16 October 2025
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Abstract
Objectives: The effects of sodium-glucose transporter 2 inhibitors (SGTL2i) in patients with lupus nephritis (LN) remain poorly studied. This study aimed to assess the SGLT2i effects in patients with LN and residual proteinuria through a retrospective before-and-after study. Methods: We included patients with LN and residual proteinuria under maintenance treatment. Proteinuria, estimated glomerular filtration rate (eGFR), haemoglobin, hematocrit, albumin, anti-double-stranded DNA antibodies and serum complements were registered quarterly 12 months before and after SGLT2 initiation. The trajectory of each parameter was evaluated by linear mixed models for repeated measurements. Patients were classified as ‘responders’ if proteinuria decreased by ≥30% after SGLT2i initiation. Results: We evaluated 53 patients, median age of 35 years (IQR 28–46), 45 (85%) female. At SGLT2i initiation, the median proteinuria was 1.7 g/g (IQR 1.0–3.0), eGFR 94 ml/min/1.73 m2 (IQR 53–114) and haemoglobin 13.4 g/dl (IQR 12.4–14.4). After initiating SGLT2i, there was a 37.6% reduction in proteinuria (95%CI −6.8% to −76.3%) in the full cohort. Thirty-two (60%) patients were responders and 21 (40%) non-responders. Before SGLT2i, the annualized eGFR slope was −6.3 ml/min/1.73 m2 (95%CI −5.7 to−6.9) and −2.9 ml/min/1.73 m2 (95%CI −2.7 to−3.1) after SGLT2i initiation (P < 0.001). The effect on eGFR was observed in responders and non-responders. The median haemoglobin and hematocrit increased by 0.78 g/dl (95%CI 0.76–0.81) and 2.33% (95%CI 2.24–2.41), respectively. Six (12%) adverse events were recorded, three (6%) events led to emergency room evaluation or hospitalization. Conclusions: In lupus nephritis the use of SGLT2i was associated with decreases in proteinuria. Beneficial changes in eGFR, haemoglobin and hematocrit trajectories after SGLT2i initiation were observed, independent of the proteinuria response.Keywords
Funding Information
- Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
This publication has 35 references indexed in Scilit:
- Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: A national cohort studySeminars in Arthritis and Rheumatism, 2025
- Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA NephropathyKidney International Reports, 2025
- Sodium-glucose cotransporter 2 (SGLT2) inhibition and autoimmunitySeminars in Arthritis and Rheumatism, 2025
- Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events, and Safety Outcomes in Patients With Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population‐Based Target Trial EmulationArthritis & Rheumatology, 2024
- Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus ErythematosusJAMA Network Open, 2024
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsThe Lancet, 2022
- Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐ ReducedEuropean Journal of Heart Failure, 2022
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathyKidney International, 2021
- Effect of dapagliflozin on anaemia in DAPA‐HFEuropean Journal of Heart Failure, 2021
- Risk of End‐Stage Renal Disease in Patients With Lupus Nephritis, 1971–2015: A Systematic Review and Bayesian Meta‐AnalysisArthritis & Rheumatology, 2016